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Abstract
Background: There are limited data on the epidemiology and risk factors of ophthalmoplegia among diabetic
patients. This study aims to determine the prevalence and important risk factors related to ophthalmoplegia among
diabetic patients.
Methods: This is an observational registry-based study using the Saudi National Diabetes Registry (SNDR) database
to select diabetic patients regardless of their diabetes type. A total of 64,351 Saudi diabetic patients aged more
than 18 years and registered in SNDR between January 2000 and December 2010 were analyzed to identify
ophthalmoplegic cases. Demographic, clinical, and biochemical parameters were studied and STROBE guidelines
were used to design and report the results of this study.
Results: The overall prevalence of ophthalmoplegia cases was 0.32 %, further distributed into: 53.11 %, 36.36 %, and
2.8 % for cranial nerves VI, III, IV palsies respectively. Ophthalmoplegic cases were predominantly type 2 diabetic
males with older age and longer diabetes duration. The most important and significant risk factors were age ≥
45 years, diabetes duration ≥ 10 years, male gender and presence of retinopathy and nephropathy.
Conclusions: Ophthalmoplegia is a rare entity associated mainly with type 2 diabetes. Clinicians have to consider
its risk factors when screening or planning for prevention of this condition.
Keywords: Ophthalmoplegia, III cranial nerve palsy, IV cranial nerve palsy, VI cranial nerve palsy, Diabetes mellitus
Background
Ophthalmoplegia is a rare entity seen in patients with
diabetes mellitus and is associated with great patients’
anxiety and may appear as a serious diagnostic and
therapeutic medical challenge. Ophthalmoplegia second-
ary to cranial nerve III, IV, and VI palsies in diabetic
patients is considered to be a form of microvascular
cranial nerve palsy involving small vessels atherosclerotic
changes, however, full recovery within 12 weeks after the
onset of symptoms is the usual outcome [1–3].
Despite extensive studies on the epidemiology of
diabetic neuropathy in general, there is a relative paucity
of knowledge regarding factors associated with ophthal-
moplegia in patients with diabetes. Most of the published
studies available in the literature have been generated
from tertiary referral centres rather than general diabetic
population [4, 5].
In a retrospective large Caucasian diabetic population
follow up, mainly type 2 diabetes, 0.4 % were hospital-
ized with ophthalmoplegia [2], while a Japanese study re-
ported the prevalence of ophthalmoplegia among
diabetic patients to be 0.97 % which is ten times more
than non-diabetic patients at 0.13 % [6]. Among Saudi
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diabetic patients, VI and III cranial nerves palsies were
found to be the most frequently affected cranial nerves
[7]. Ophthalmoplegia in diabetic patients are more fre-
quently seen in older individuals with a long duration
of diabetes [6]. Other risk factors are chronic diabetes
micro and macroangiopathies namely: retinopathy, ne-
phropathy, neuropathy and major vessel diseases [8].
Diabetes registry is a valuable source of clinical data
that can be used to study rare conditions associated with
diabetes. The Saudi National Diabetes Registry (SNDR)
hosts large number of diabetic patients with different
types of diabetes and a wide age spectrum. Over the past
14 years, this registry has collected information from a
wide range of diabetic patients suffering from different
cranial nerve palsies. Utilizing this registry, we performed
a cross sectional prevalence study for ophthalmoplegia
secondary to cranial nerves III, IV, and VI palsies and its
related risk factors for patients who are older than
18 years of age regardless of their diabetes type.
Methods
Study population
This is an observational registry-based study using the
data collected from patients’ hospital files for a spe-
cially designed electronic web-based data system that
includes demographic data and diabetes related clinical
and biochemical parameters in the Kingdom of Saudi
Arabia. The design and development of the web-based
SNDR has been explained in a previously published
paper [9]. SNDR is one of the strategic research pro-
jects of Saudi Arabia which was approved and funded
by King Abdulaziz City for Science and Technology
(KACST) and can be accessed at http://www.diabetes.
org.sa/diabetes/frames.html by authorized users only. The
study was approved by the institutional review board in
King Khalid Eye Specialist hospital and the data used in
this study was not consented since it does not comprom-
ise anonymity or confidentiality or breach of local data
protection laws.
A cohort of 67,075 diabetic patients registered between
January 2000 and December 2010 was used in this study
after completing and validating their data. All patients
aged less than 18 years were excluded and a total of
64,351 patients aged ≥ 18 years old were used to assess
the prevalence and risk factors associated with III, IV, and
VI cranial nerve palsies.
Study variables
Patients were classified according to their diabetes type
into type 1, type 2, impaired glucose tolerance (IGT),
and secondary diabetes as per their present status in the
registry database and using American Diabetes Asso-
ciation criteria (ADA) [10]. Chronic diabetes compli-
cations including: neuropathy in the form of autonomic
or polyneuropathy, retinopathy in the form of non-
proliferative diabetic retinopathy (NPDR) or proliferative
diabetic retinopathy (PDR) with or without macular
oedema (ME), nephropathy in the form of microalbu-
minuria, marcoalbuminurea or end stage renal disease
(ESDR) and vasculopathy in the form of cerebrovascular
disease (CVD), were recorded if they were documented
in the patients’ files.
Patients were classified according to their HbA1c
level into well controlled (≤ 7 %) and poorly controlled
(> 7 %) using HbA1c value during the last registry visit.
Patients were considered hypertensive or hypelipidemic if
it was documented in their hospital files or if they were
on treatment. All patients using insulin during their
registry period were identified as insulin users regardless
of their diabetes type.
Ophthalmoplegia classification
Based on the notes of the ophthalmologist in the patients’
files, ophthalmoplegia was reported when one or more of
the following cranial nerves; III, IV, or VI were affected.
The oculomotor (III) cranial nerve palsy was considered
when it was clearly documented in the patient’s file with
one or more of the following signs: droopy lid, restricted
upward ocular motility and binocular diplopia [11]. The
trochlear (IV) cranial nerve palsy was considered if it was
reported that the patient presented with vertical diplopia,
which is commonly accompanied by compensatory contra
lateral head tilt, while abducens (VI) nerve palsy was
considered if the ophthalmologist indicated that the pa-
tient had binocular horizontal diplopia and esotropia in
primary gaze [12].
All the reported ophthalmoplegic cases were consi-
dered to be associated with diabetes if diabetes preceded
the onset of ophthalmoplegia and other causes had been
excluded by the treating physicians based on the patients’
files review. However, neither the duration nor the recov-
ery status of the reported cases were collected.
Statistical analysis
The strengthening reporting of observational study in
epidemiology (STROBE) guidelines was used to design
and report this study. All data were analyzed using
Statistical Package for Social Studies (SPSS 22; IBM
Corp., New York, NY, USA). Descriptive and frequency
analyses were calculated for all variables. The Chi square
test (χ2) was used for statistical validation of qualitative
variables such as, gender and smoking status. Student’s
t-test was used for continuous variables such as age,
duration of diabetes BMI and HbA1c. Imputation, based
on a regression model, was used to estimate missing
data. Risk factors were assessed using univariate, age and
gender adjusted, and multivariate logistic regression
models. Odds ratio (OR) and its 95 % confidence intervals
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(CI) were used to express different risks. A p-value of
< 0.05 was chosen as the level of significance.
Results
Out of the total studied cohort, 209 (0.32 %) patients
were found to be suffering from ophthalmoplegia, where
males contributed to 72.73 %, while females contributed
to 27.27 % (Fig. 1). A total of 111 patients (53.11 %) had
VI cranial never palsy and 76 patients (36.36 %) had III
cranial nerve palsy. Patients with IV cranial nerve palsy
accounted only for 2.87 % (6 patients), while 16 patients
(7.66 %) were suffering from more than one nerve palsy.
Ophthalmoplegic patients were significantly older (p <
0.0001), having lower body mass index (BMI) (p =
0.015) and longer diabetes duration (p < 0.0001) when
compared with non affected patients. There was no
significant difference in the mean HbA1c and fasting
blood sugar (FBS) between affected and non-affected pa-
tients, while random blood sugar (RBS) was significantly
higher among affected cases (Table 1).
Males predominated ophthalmoplegia cases at 72.73 %
in both III and VI nerve palsies and all the patients who
had IV nerve palsy were males. There were 47.85 % of
the ophthalmoplegic patients aged 65 years and older
and the rest ( 48.80 %) were between 45 and 64 years of
age. We did not report III or IV nerve palsies among
those who are younger than 45 years of age. The
majority of ophthalmoplegic cases were having BMI
more than 25 kg/m2.
Type 2 diabetic patients accounted for 99.40 % of all
ophthalmoplegic cases found in this study further di-
vided into: 36.71 % with III, 2.90 % with IV, 52.66 % with
VI nerves palsies and 7.73 % subjects with multiple cra-
nial nerve involvement. There were only 0.69 % type 1
diabetic patients and all had VI nerve palsy only. There
were no cases of ophthalmoplegia found among either
IGT or secondary diabetes patients. Over eighty-five per-
cent of the ophthalmoplegic cases had diabetes duration of
≥ 10 years. Smoking was only found in 4.31 % of the af-
fected cases. Out of the total affected cases, 67.94 % had
HbA1c > 7 and 36.84 % were insulin users.
Polyneuropathy and autonomic neuropathy affected
only 2.87 and 1.91 % respectively of ophthalmoplegic
cases. Polyneuropathy was not found to be associated
with either IV or III cranial nerves palsies, while auto-
nomic neuropathy was not associated with IV cranial
nerve palsy. Ophthalmoplegia was highly associated with
NPDR and PDR, with less association with ME at 52.53
%, 47.37 % and 23.92 % respectively. This association
was observed for any cranial nerve palsy but not for
PDR and ME in IV cranial nerve palsy patients. When
compared with other complications, diabetic nephropa-
thy had lower but significant association with ophthalmo-
plegia, however, no cases with diabetic nephropathy had
suffered from IV cranial nerve palsy. Among ophthalmo-
plegic patients, only 4.31 % reported cerebrovascular dis-
ease, which was similar to the non-affected patients.
Hypertension was found in 48.33 % of the ophthalmople-
gic patients, where approximately 50 % of patients with
VI nerve palsy were suffering from hypertension. The
presence of hyperlipidemia was significantly lower among
ophthalmoplegic patients, when compared with non-
affected cases at 24.40 % and 35.42 % respectively
(Table 2).
Figure 2 demonstrates the univariate analysis of diffe-
rent risk factors of ophthalmoplegia. Age ≥ 45 years and
the presence of diabetic retinopathy were the most
important and highly significant risk factors for ophthal-
moplegia with OR (95 % CI) of 8.03 (3.71–17.37) and
7.31 (5.21–10.27). Other significant risk factors were
diabetes duration ≥ 10 years, male gender, and the pre-
sence of diabetic nephropathy with OR (95 % CI) of
Fig. 1 Flow diagram for ophthalmoplegia cases identified among patients ≥ 18 years during the period from 2000 to 2010 using the Saudi
National Diabetes registry database
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3.54 (2.34–5.33), 2.28 (1.63–3.18), and 2.01 (1.30–3.10)
respectively. BMI ≥ 30 kg/m2, hypertension and poor
glycemic control were not found to be significant risk
factors, while hyperlipidemia showed a significantly
lower risk for ophthalmoplegia.
Table 3 demonstrates the age and gender adjusted in
addition to the multivariate regression analysis models
for the significant risk factors shown in the univariate
analysis. Age and gender adjusted regression analysis
demonstrated that, diabetic retinopathy and nephro-
pathy in addition to diabetes duration ≥10 years to be
significant and important risk factors. All the five recog-
nized risk factors have proven to be independent when
using the multivariate regression analysis, except diabetic
nephropathy.
Discussion
From our large diabetes registry cohort, this study
estimated the prevalence of ophthalmoplegia related to
VI, III, and IV cranial nerves palsies to be 0.320 %
(0.316–0.324), while it was 0.5 %, 0.4 % and 0.5 % in the
Italian studies in 2011 and 2009 and the Japanese study
in 1990 respectively [4–6]. Although ophthalmoplegia is
a well-known rare entity associated with diabetes, it is
reported to be 10 times more frequent than non-diabetic
subjects [6]. Cranial nerves involved in ophthalmoplegia
had a wide range of frequency as shown in this study,
where the most frequent cranial nerve palsy was cranial
nerve VI followed by III and IV in the same order.
Multiple cranial nerve involvement was found in only
7.6 % of the cases. Although, both the Italian and
Japanese studies have shown the third cranial nerve
palsy to be the most frequently affected nerve [4, 6],
other case report studies from USA, France and UK
support our findings that, sixth cranial nerve palsy is the
most frequently affected nerve among diabetic patients
[13–15]. This was also the same observation reported
from a prospective study in a tertiary hospital in Saudi
Arabia reported in 1999 [7]. As shown in Table 4, both
Italian and Japanese studies did not report any fourth
cranial nerve palsy which is known for its very low fre-
quency and diagnosis difficulties. This could be ex-
plained by the effect of the small sample which was not
the case in our study since we had large cohort and have
shown that the fourth cranial nerve palsy frequency to
be 2.9 %. This is also supported by findings from France
and USA case studies [13, 14], where the large number
of ophthalmoplegic cases had shown the frequency of
the IV nerve palsy ranging from 6 to 6.7 %. Previous
local data have shown fourth nerve palsy frequency to
be close to our observation in this study at 2 % [7]. The
most likely explanation for the high frequency of VI cra-
nial nerve palsy is related to its significant length [16]
which would expose it more to ischemia secondary to
angiopathic changes. The frequancy of the involvement
of the multiple cranial nerves in our study is similar to
what has been reported from other ethnicities except for
the Japanese diabetic cohort, where it had reached up to
20 % [6].
This study shows that male gender predominated all
cases with ophthalmoplegia which was the same
observation in Caucasian and Chinese ethnicities [4, 17].
Although ophthalmoplegia is considered to be a condi-
tion that affects people after their fifth decade, we are
reporting 3.35 % of ophthalmoplegic cases in patients
younger than 45 years of age involving mainly cranial
nerve VI. The mean BMI for ophthalmoplegic cases in our
study demonstrated significantly lower value than non-
affected patients although; approximately 80 % of ophthal-
mologic cases had BMI ≥25 kg/m2. We did not report any
ophthalmoplegic cases linked to secondary diabetes or
IGT patients that could be due to the fact that these two
conditions are associated with lower diabetes complica-
tions but this observation warrants further studies. Similar
to other studies [4, 5], we have also observed that, the vast
majority of ophthalmoplegic cases were type 2 diabetic pa-
tients, while type 1 was found in less than 1 % of the cases
in our study and all were suffering from sixth cranial
nerve palsy only. Insulin users were significantly more fre-
quent among ophthalmoplegic patients. This could be
Table 1 Descriptive analysis of clinical and biochemical characteristics for the patients with or without ophthalmoplegia in the study
cohort Sample according to cranial nerve palsy
Variables Total sample
(n = 64,351)













Mean Age 55.92 ± 14.50 55.89 ± 14.51 63.25 ± 9.59 <0.0001 65.17 ± 8.04 64.17 ± 9.11 61.47 ± 9.92 66.13 ± 12.27
Mean BMI 30.47 ± 6.48 30.48 ± 6.48 29.24 ± 5.30 0.015 28.93 ± 5.43 27.20 ± 2.08 29.49 ± 5.28 29.75 ± 6.09
Mean DM duration 13.17 ± 8.05 13.15 ± 8.05 17.90 ± 7.59 <0.0001 17.15 ± 6.86 14.67 ± 4.50 18.20 ± 8.21 20.50 ± 6.93
Mean HbA1c 8.88 ± 2.39 8.88 ± 2.39 8.75 ± 2.19 0.791 9.14 ± 2.32 9.50 ± 0.00 8.45 ± 2.28 8.10 ± 2.12
Mean FBS (mmol/l) 10.02 ± 4.40 10.02 ± 4.40 10.53 ± 4.42 0.402 10.98 ± 4.92 8.60 ± 3.21 10.61 ± 4.35 8.70 ± 0.71
Mean RBS (mmol/l) 12.82 ± 5.63 12.81 ± 5.63 14.87 ± 5.58 0.005 14.52 ± 5.56 15.55 ± 0.21 14.94 ± 5.77 15.59 ± 6.56
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explained by the fact that insulin users, especially type
2, had worse diabetes or that insulin has a direct neuro-
toxic effect [18, 19]. There was no differnce in the
frquancy of the cerebrovascular disease between patients
with or without ophthalmoplegia.
The most important and highly significant risk factor
for ophthalmoplegia in our study was the age ≥ 45 years
which was an independent risk factor when multivariate
regression analysis was performed which is in consist-
ence with the observation of the vast majority of studies
comparing the frequency of this condition in patients
before and after 45 years of age [20]. The second impor-
tant risk factor was the presence of diabetic retinopathy
which was also an independent risk factor when adjust-
ing for age and gender or performing multivariate ana-
lysis. Diabetic retinopathy either mild (NPDR), or sight
threatening (PDR and ME) were significantly more fre-
quent in the ophthalmoplegia cases which is in line with
findings of many previous reports [2, 3, 21]. The high
frequency of retinopathy among cranial palsy cases could

















n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Gender Male 33,718 (52.40) 33,566 (52.33) 152 (72.73) < 0.0001 54 (35.53) 6 (3.95) 77 (50.66) 15 (9.87)
Female 30,633 (47.60) 30,576 (47.67) 57 (27.27) < 0.0001 22 (38.60) 0 (0.00) 34 (59.65) 1 (1.75)
Age (years) 18-44 years 12,916 (20.07) 12,909 (20.12) 7 (3.35) < 0.0001 0 (0.00) 0 (0.00) 6 (85.71) 1 (14.29)
45-64 years 31,914 (49.59) 31,812 (49.60) 102 (48.80) 0.819 34 (33.33) 3 (2.94) 60 (58.82) 5 (4.90)
≥ 65 years 19,521 (30.34) 19,421 (30.28) 100 (47.85) < 0.0001 42 (42.00) 3 (3.00) 45 (45.00) 10 (10.00)
Marital status Single 3,576 (5.55) 3,574 (5.57) 2 (0.96) 0.004 0 (0.00) 0 (0.00) 2 (100.00) 0 (0.00)
Married 57,567 (89.46) 57,376 (89.45) 191 (91.38) 0.263 71 (37.17) 5 (2.62) 99 (51.83) 16 (8.38)
Divorced 642 (1.00) 640 (1.00) 2 (0.96) 0.953 0 (0.00) 0 (0.00) 2 (100.00) 0 (0.00)
Widow 2,566 (3.99) 2,552 (3.98) 14 (6.70) 0.450 5 (35.71) 1 (7.14) 8 (57.14) 0 (0.00)
BMI 18-24.9 11,841 (18.40) 11,797 (18.39) 44 (21.05) 0.322 21 (47.73) 1 (2.27) 19 (43.18) 3 (6.82)
25-29.9 21,107 (32.80) 21,023 (32.78) 84 (40.19) 0.023 27 (32.14) 5 (5.95) 45 (53.57) 7 (8.33)
≥ 30 31,403 (48.80) 31,322 (48.83) 81 (38.76) 0.004 28 (34.57) 0 (0.00) 47 (58.02) 6 (7.41)
Type of Diabetes Type 1 4,368 (6.79) 4,366 (6.81) 2 (0.96) 0.001 0 (0.00) 0 (0.00) 2 (100.00) 0 (0.00)
Type 2 59,270 (92.11) 59,063 (92.08) 207 (99.04) < 0.0001 76 (36.71) 6 (2.90) 109 (52.66) 16 (7.73)
IGT 659 (1.02) 659 (1.03) 0.0 (0.0) 0.284 0 0 0 0
Secondary DM 54 (0.08) 54 (0.08) 0.0 (0.0) 0.675 0 0 0 0
Diabetes duration < 10 24,273 (37.72) 24,243 (37.80) 30 (14.35) < 0.0001 10 (33.33) 1 (3.33) 18 (60.00) 1 (3.33)
≥ 10 40,078 (62.28) 39,899 (62.20) 179 (85.65) < 0.0001 66 (36.87) 5 (2.79) 93 (51.96) 15 (8.38)
Smoking 4,183 (6.50) 4,174 (6.51) 9 (4.31) 0.213 3 (33.33) 0 (0.00) 5 (55.56) 1 (11.11)
HbA1c ≤ 7 14,992 (23.30) 14,925 (23.27) 67 (32.06) 0.003 21 (31.34) 2 (2.99) 38 (56.72) 6 (8.95)
> 7 49,359 (76.70) 49,217 (76.73) 142 (67.94) 0.003 55 (38.73) 4 (2.82) 73 (51.41) 10 (7.04)
Insulin users 19,756 (30.70) 19,679 (30.68) 77 (36.84) 0.053 32 (41.56) 1 (1.30) 37 (48.05) 7 (9.09)
Neuropathy Poly neuropathy 5,832 (9.06) 5,826 (9.08) 6 (2.87) 0.002 0 (0.00) 0 (0.00) 5 (83.33) 1 (16.67)
Autonomic neuropathy 1,933 (3.00) 1,929 (3.01) 4 (1.91) 0.538 2 (50.00) 0 (0.00) 2 (50.00) 0 (0.00)
Retinopathy NPDR 5,123 (7.96) 5,013 (7.82) 110 (52.63) < 0.0001 36 (32.73) 6 (5.45) 62 (56.36) 6 (5.46)
PDR 6,146 (9.55) 6,047 (9.43) 99 (47.37) < 0.0001 40 (40.40) 0 (0.00) 49 (49.50) 10 (10.10)
ME 2,914 (4.53) 2,864 (4.47) 50 (23.92) <0.0001 16 (32.00) 0 (0.00) 29 (58.00) 5 (10.00)
Nephropathy 6,280 (9.76) 6,245 (9.74) 35 (16.75) 0.01 11 (31.43) 0 (0.00) 17 (48.57) 7 (20.00)
Cerebrovascular disease 2,817 (4.38) 2,808 (4.38) 9 (4.31) 0.960 3 (33.33) 1 (11.11) 4 (44.45) 1 (11.11)
Hypertension 29,455 (45.77) 29,354 (45.76) 101 (48.33) 0.458 38 (37.62) 1 (0.99) 49 (48.52) 13 (12.87)
Hyperlipidemia 22,767 (35.38) 22,716 (35.42) 51 (24.40) 0.001 22 (43.14) 1 (1.96) 26 (50.98) 2 (3.92)
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be explained by the fact that both diseases arise from the
microvascular abnormalities that are associated with
diabetes and its related co-morbid factors [8]. Diabetes
duration ≥ 10 years is a significant independent risk
factor for ophthalmoplegia among this cohort which was
also observed among Caucasian since it was known to
be the disease of older age and longer diabetes duration
[22]. Similar to other mononeuropathies, male gender in
our study was an independent risk factor for ophthalmo-
plegia wherein males were more frequently affected than
females as has been observed by Gaeco D et al. [5]
among Caucasian diabetic patients. The current study
proves that, diabetic nephropathy is a significant risk
factor when univariate and age and gender adjusted re-
gression analysis were conducted, but it was not an
independent risk factor for ophthalmoplegia as proven
Fig. 2 Univariate analysis of the different ophthalmoplegia risk factors
Table 3 Age and gender–adjusted, and multivariate–adjusted odds ratio and 95 % confidence intervals of risk factors for the
ophthalmoplegia cases in the studied cohort
Risk factors Age and gender adjusted Multivariate adjusted
OR 95 % CI p-value OR 95 % CI p-value
Age≥ 45 years - - - 3.54 1.57–7.97 0.002
Male gender - - - 2.09 1.41–3.08 < 0.0001
Diabetic retinopathy 5.72 4.04–8.11 < 0.0001 4.32 2.94–6.35 < 0.0001
DM duration ≥ 10 years 3.11 2.01–4.80 < 0.0001 1.92 1.19–3.09 0.007
Diabetic nephropathy 1.66 1.06–2.59 0.026 0.86 0.52–1.43 0.570
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by the multivariate analysis. Although obesity and poor
glycemic control were expected to be significant risk
factors for ophthalmoplegia, in the current analysis and
similar to the findings of Ostricet al., and Kobashi et al.
[21, 23], their effect was found to be not significant
which could be related to the high frequency of the two
factors in both affected and non-affected patients in our
cohort. Hypertension did not increase the risk of oph-
thalmoplegia significantly in the current analysis, which
is in line with the findings of Pateland Coll [24] where
hypertension was not an independent risk factor. How-
ever, it is noteworthy that hypertension may worsen the
effect of diabetes in ischemic nerve palsies, especially
when the same study reported that the combination of
diabetes and hypertension was associated with eightfold
increased risk of six nerve palsy [24]. Unexpectedly
hyperlipidemia was found to be a significant protective
factor with an OR of 0.65 and p value = 0.014. This
could be the effect of lipid lowering agents since all
hyperlipidemic patients are receiving lipid lowering
therapy.
Our study is limited by its hospital-based retrospective
nature that lacks certain specific information and with
being a cross-sectional study which is not the right set
up for determining causality. Another limitation of this
study is the lack of temporal relation between HbA1c
and the onset of ophthalmoplegia and the possibility of
wrong coding or missing any codes.
However, our study draws its strength from being a
large diabetes registry cohort that was extensively inves-
tigated for diabetes and its co-morbidities.
Conclusion
Ophthalmoplegia secondary to III, IV and VI cranial
nerve palsies among Saudi diabetic patients is a rare
entity similar to what has been observed in other ethnic-
ities. This study has shown that age ≥ 45 years, retinop-
athy, diabetes duration ≥ 10, male gender, and diabetic
nephropathy to be the most significant risk factors asso-
ciated with ophthalmoplegia. We could not find any
cases of ophthalmoplegia among patients with secondary
diabetes and IGT, and it was even very rare among type
1 diabetic patients. This study provided a better insight
on the prevalence of ophthalmoplegia and its different
cranial nerves palsies and the important risk factors that
clinicians should consider when screening for this rare
condition.
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Table 4 Studies looked at ophthalmoplegic cases in diabetic population
Study design Study sample Number
of cases
Prevalence Cranial nerve palsy
VI III IV Multiple
Saudi Arabia (current) Registry based 64,351 209 0.32 % 53.1 36.4 2.9 7.6
Italy (2011) [1] Hospital based 8150 61 0.5%a 27.3 % 65.9 % - 6.8 %
Japan (1990) [6] Hospital based 1961 10 0.5%a 20 % 60 % - 20 %
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aPrevalence recalculated excluding VII cranial nerve palsy
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